6/2/2020 7:16:40 AM
BioCryst Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/27/2020 11:45:03 PM
BioCryst Pharma Prices Public Offering Of 18.7 Mln Shares At $4.50/Shr
4/3/2020 7:10:10 AM
BioCryst Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/2/2020 7:09:24 AM
BioCryst Pharma Appoints Anthony Doyle As SVP And CFO
3/16/2020 7:20:37 AM
BioCryst Announces New Data From The APeX-2 Trial
2/18/2020 7:15:00 AM
BioCryst Pharma Says FDA Accepts NDA For Oral, Once Daily Berotralstat To Prevent HAE Attacks
2/3/2020 7:06:14 AM
BioCryst Submits JNDA For Oral, Once Daily Berotralstat For Prophylactic Treatment Of Hereditary Angioedema
1/6/2020 7:13:33 AM
BioCryst Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
9/26/2019 7:36:27 AM
U.S. Department Of Health And Human Services Exercises Option For Additonal Rapivab For Strategic National Stockpile
9/23/2019 7:11:55 AM
BioCryst Pharma Appoints Helen Thackray To Board
9/4/2019 7:05:34 AM
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7/3/2019 7:35:19 AM
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7/1/2019 7:43:03 AM
BioCryst Pharma Appoints Megan Sniecinski As Chief Business Officer
5/21/2019 7:07:36 AM
BioCryst Says Oral BCX7353 Meets Primary Endpoint In Phase 3 APeX-2 Trial